The state of Texas currently has 30 active clinical trials seeking participants for Multiple Sclerosis research studies. These trials are conducted in various cities, including Houston, Dallas, San Antonio and Austin.
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis or Progressive Forms of Multiple Sclerosis
Recruiting
The purpose of this study is to evaluate the safety, tolerability, efficacy, and drug levels of CC-97540 in participants with Relapsing Forms of Multiple Sclerosis (RMS) or Progressive Forms of Multiple Sclerosis (PMS).
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
03/20/2024
Locations: Local Institution - 0006, Dallas, Texas
Conditions: Multiple Sclerosis
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
Recruiting
This phase Ib trial studies the side effects of nivolumab and to see how well it works in treating patients with autoimmune disorders and cancer that has spread to other places in the body or cannot removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/19/2024
Locations: UT Southwestern Simmons Cancer Center - RedBird, Dallas, Texas +4 locations
Conditions: Autoimmune Disease, Crohn Disease, Dermatomyositis, Inflammatory Bowel Disease, Multiple Sclerosis, Rheumatoid Arthritis, Sjogren Syndrome, Systemic Lupus Erythematosus, Systemic Scleroderma, Ulcerative Colitis, Hematopoietic and Lymphoid Cell Neoplasm, Psoriasis, Psoriatic Arthritis, Malignant Solid Neoplasm
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
Recruiting
A study to evaluate the efficacy and safety of fenebrutinib on disability progression and relapse rate in adult participants with RMS. Eligible participants will be randomized 1:1 to either fenebrutinib or teriflunomide. Open-Label Extension (OLE) phase is contingent on a positive benefit-risk result in the Primary Analysis of the study.
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
03/15/2024
Locations: North Texas Institute of Neurology and Headache NextStage Clinical Research Clinic, Plano, Texas +1 locations
Conditions: Relapsing Multiple Sclerosis
The MS-LINK™ Outcomes Study
Recruiting
The Multiple Sclerosis (MS) Leadership and Innovation Network (MS-LINK™) is comprised of networks working cooperatively to advance Multiple Sclerosis (MS) science and improve MS participant outcomes. In this study participants will be followed from the time of consent through the lifetime of the study (currently 3 years), unless the participant chooses to withdraw from the study. Collection of participant's medical history, including MS and treatment history, will be automated through extraction... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/15/2024
Locations: The University of Texas of Austin, Austin, Texas +1 locations
Conditions: Multiple Sclerosis
Next-Gen MS: Feed-forward PRO Data for MS Research
Recruiting
This Next Generation learning health system for Multiple Sclerosis (Next-Gen MS) study is a sub-study of the MS-LINK™ Outcomes Study (NCT04735406). The study aims to examine the effects of using feed forward Patient Reported Outcomes (PROs) data in real-world Multiple Sclerosis (MS) care settings. The study will be conducted within an emerging Learning Healthcare System (LHS).
Gender:
All
Ages:
18 years and above
Trial Updated:
03/15/2024
Locations: The University of Texas of Austin, Austin, Texas +1 locations
Conditions: Multiple Sclerosis (MS)
A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis
Recruiting
This study will evaluate the efficacy and safety of ocrelizumab ( Ocrevus®) compared with placebo in participants with primary progressive multiple sclerosis (PPMS), including participants later in their disease course. This study focuses on upper limit disability progression. This study will consist of the following phases: screening, double-blind treatment, follow-up 1 (FU1), an optional open-label extension (OLE), follow-up 2 (FU2), and B-cell monitoring (BCM).
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
03/13/2024
Locations: Maxine Mesinger MS Clinic/Baylor College of Medicine; Neurology, Houston, Texas
Conditions: Multiple Sclerosis, Primary Progressive
A Study To Evaluate Safety And Efficacy Of Ocrelizumab In Comparison With Fingolimod In Children And Adolescents With Relapsing-Remitting Multiple Sclerosis
Recruiting
This double-blind, double-dummy study will evaluate the safety and efficacy of ocrelizumab compared with fingolimod in children and adolescents with relapsing-remitting multiple sclerosis aged between 10 and < 18 years over a duration of at least 96 weeks.
Gender:
All
Ages:
Between 10 years and 17 years
Trial Updated:
03/13/2024
Locations: Baylor College of Medicine/Texas Children's Hospital, Houston, Texas
Conditions: Relapsing-Remitting Multiple Sclerosis
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
Recruiting
To evaluate the safety and efficacy of fingolimod vs. interferon beta-1a i.m. in pediatric patients with multiple sclerosis (MS)
Gender:
All
Ages:
Between 10 years and 17 years
Trial Updated:
03/12/2024
Locations: Novartis Investigative Site, San Antonio, Texas
Conditions: Multiple Sclerosis
Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial
Recruiting
FDA-approved multiple sclerosis (MS) disease-modifying therapies (DMTs) target the relapsing phase of MS but have minimal impact once the progressive phase has begun. It is unclear if, in the relapsing phase, there is an advantage of early aggressive therapy with respect to preventing long-term disability. The infectious risks and other complications associated with higher-efficacy treatments highlight the need to quantify their effectiveness in preventing disability. The TRaditional versus Ear... Read More
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
02/28/2024
Locations: Baylor Scott and White Health, Dallas, Texas +2 locations
Conditions: Multiple Sclerosis, Relapsing-Remitting
Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects With Relapsing-Remitting Multiple Sclerosis
Recruiting
This is a randomized, double-blind study of PIPE-307 or placebo in subjects with relapsing-remitting multiple sclerosis. Subjects will be randomized into 1 of 3 separate cohorts (1:1:1 randomization ratio, PIPE-307 Dose A:PIPE-307 Dose B: Placebo) for a total duration of approximately 30 weeks.
Gender:
All
Ages:
Between 18 years and 50 years
Trial Updated:
02/28/2024
Locations: Clinical Trial Network, Houston, Texas +1 locations
Conditions: Relapsing Remitting Multiple Sclerosis
Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis
Recruiting
This study is a prospective, multi-center, randomized, double blinded, placebo-controlled study of OCR treatment-discontinuation in patients with early RMS. All eligible participants will be initiated on OCR using the standard approved administration schedule of two 300 mg infusions separated by 14 days (i.e., Days 0 and 14) for a total of 600 mg, followed by 600 mg infusions at Month 6 and Month 12. At Month 12, participants will be randomized (1:1:1) to one of three Arms with randomized treatm... Read More
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
02/20/2024
Locations: University of Texas Southwestern Medical Center, Dallas, Texas +1 locations
Conditions: Multiple Sclerosis
Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis
Recruiting
Efficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis
Gender:
All
Ages:
Between 10 years and 17 years
Trial Updated:
02/18/2024
Locations: University of Texas Southwestern Main Center, Dallas, Texas
Conditions: Multiple Sclerosis (MS)